Chronic kidney disease and cardiovascular disease are emerging public health problems in the United States and worldwide,[@ref1] [@ref2] and these two diseases seem to have a complex relation.[@ref3] [@ref4] [@ref5] For example, the prevalence of traditional risk factors for cardiovascular disease is increased in patients with impaired kidney function,[@ref4] and these risk factors predict the start of chronic kidney disease.[@ref6] [@ref7] [@ref8] [@ref9] Furthermore, several studies suggest an association between impaired kidney function and cardiovascular disease as well as mortality from all causes[@ref10] [@ref11] [@ref12] [@ref13] [@ref14] [@ref15] and specifically from cardiovascular disease.[@ref16] Most studies of the association between kidney function and cardiovascular disease or mortality have been limited to individuals at high risk for cardiovascular disease, with existing cardiovascular disease, or with severely impaired kidney function.

However, studies of the association between impaired kidney function and cardiovascular disease among people not selected on the basis of cardiovascular risk or impaired kidney function showed less consistent results.[@ref16] [@ref17] [@ref18] [@ref19] We therefore evaluated the association between kidney function and cardiovascular disease as well as mortality in the prospective Women's Health Study among more than 27 939 women who were at least 45 years old and did not have cardiovascular disease or other major disease, including symptomatic kidney disease, at study entry.

Methods
=======

Study population
----------------

We conducted a prospective cohort study among participants in the Women's Health Study, a completed randomised placebo controlled trial designed to test the benefits and risks of low dose aspirin and vitamin E in the primary prevention of cardiovascular disease and cancer. The study's design, methods, and results have been described in detail previously.[@ref20] [@ref21] [@ref22] Briefly, a total of 39 876 US female health professionals aged ≥45 years at study entry (1992-5), who were mostly white (94%), and without a history of cardiovascular disease, cancer, or other major illnesses were randomly assigned to aspirin (100 mg on alternate days), vitamin E (600 IU on alternate days), both active agents, or both placebos. All participants provided written informed consent and the Institutional Review Board of Brigham and Women's Hospital (Boston MA, USA) approved the study. Baseline information was self reported and collected by a mailed questionnaire that asked about many cardiovascular risk factors and lifestyle variables.

Blood measurements
------------------

Blood samples were collected from 28 345 participants before randomisation. Of those, 406 samples could not be analysed because of technical limitations, leaving 27 939 participants for analysis. All blood samples were collected in tubes containing EDTA and stored in vapour phase liquid nitrogen (−170°C). In a core laboratory certified by the National Heart, Lung, and Blood Institute-Centers for Disease Control and Prevention Lipid Standardisation Program, samples were analysed for lipids and a panel of inflammatory biomarkers. Creatinine was measured by a rate blanked method that is based on the Jaffé reaction. Total cholesterol was assayed with reagents from Roche Diagnostics (Basel, Switzerland) and high sensitivity C reactive protein concentrations were measured with immunoturbidimetric assays on a Hitachi 917 analyser (Roche Diagnostics, Indianapolis, USA) using reagents and calibrators from Denka Seiken (Tokyo, Japan).

Kidney function
---------------

As the primary measure of kidney function, we estimated glomerular filtration rate (GFR) by the abbreviated prediction equation developed from the Modification of Diet in Renal Disease Study,[@ref23] as recommended by the National Kidney Foundation[@ref24]:

1.  Estimated GFR (in ml/min/1.73 m^2^) = 186 × \[serum creatinine (in mg/dl)^−1.154^ × Age^−0.203^ × 0.742 (female) × 1.210 (if black)\]

We categorised participants based on their estimated GFR as \<60, 60-74.9, 75-84.0, and ≥90 ml/min/1.73 m^2^, based on the classification of the National Kidney Foundation.[@ref24] In sensitivity analyses, we also evaluated categories of GFR of \<40 ml/min/1.73 m^2^ with risks of cardiovascular disease. We had too few participants in lower categories of GFR to perform meaningful analyses.

As a secondary measure for kidney function, we used plasma creatinine concentration, which we categorised according to the following centile cut-offs: \<50th (≤0.71 mg/dl, ≤63 μmol/l), 50-74th (0.72-0.79 mg/dl, 64-70 μmol/l), 75-94th (0.80-1.00 mg/dl, 71-88 μmol/l), and ≥95th (≥1.01 mg/dl, ≥89 μmol/l).

Outcome ascertainment
---------------------

During follow-up, participants self reported cardiovascular events and coronary revascularisations. Medical records were obtained for all these events and reviewed by an endpoints committee of physicians. The occurrence of myocardial infarction was confirmed if symptoms met World Health Organization criteria and if the event was associated with abnormal levels of cardiac enzymes or diagnostic electrocardiograms. Non-fatal stroke was confirmed if the participant had a new focal-neurological deficit of sudden or rapid onset that persisted for \>24 hours and attributed to a cerebrovascular event, and was classified into its major subtypes based on available clinical and diagnostic information with excellent interobserver agreement.[@ref25] Deaths were confirmed by review of autopsy reports, death certificates, medical records, or information obtained from next of kin or family members and classified according to its cause.

The primary outcome was any first cardiovascular event, a combined end point defined as the first of any of these events: non-fatal stroke, non-fatal myocardial infarction, coronary revascularisation procedures, or death from cardiovascular disease. We also evaluated the association between kidney function with any first individual cardiovascular event, all-cause mortality, and non-cardiovascular mortality.

Statistical analyses
--------------------

We compared baseline characteristics of participants according to GFR categories. To compare mean response among the categories, we used analyses of covariance adjusting for age. We used direct standardisation to adjust categorical variables and incidence rates for cardiovascular disease for age in 5-year increments.

We used Cox proportional hazards models to evaluate the association of GFR and plasma creatinine categories with the various outcomes. We calculated hazard ratios adjusted for age and for multiple variables and their 95% confidence intervals. The multivariable models controlled for age (continuous), systolic blood pressure categories (10 mm Hg increments), antihypertensive treatment (yes, no), smoking (never, past, current), body mass index (\<25, 25-29.9, ≥30 kg/m^2^), alcohol consumption (rarely/never, \<1 drink/week, 1-6 drinks/week, ≥1 drinks/day), exercise (rarely/never, \<1 time/week, 1-3 times/week, ≥4 times/week), total cholesterol concentration (quartiles), C reactive protein concentration (quartiles), postmenopausal hormone use (never, past, current), history of diabetes (yes, no), as well as randomised treatment assignments. We incorporated a missing value indicator to the multivariable models if the number of women with missing information on covariates was \>100 or assigned missing information to the reference or the past user category, if applicable.

We tested the proportionality assumption by including an interaction term for GFR category with person time in the Cox models and found no statistically significant violation.

We evaluated whether the association between GFR and any cardiovascular disease or all-cause mortality was modified by age (\<55, 55-64, ≥65 years), body mass index (\<25, 25-\<30, and ≥30 kg/m^2^), history of hypertension (systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mm Hg, or use of antihypertensive drugs), smoking status (never, past, current), C reactive protein (\<10, 10-29, ≥30 mg/l) and total cholesterol concentration (\<5.18, 5.18-6.19, ≥6.22 mmol/l). We checked for significant effect modification by adding appropriate indicator variables to the models and compared nested models by using χ^2^ statistics. We calculated P for trend across median values of the glomerular filtration rate and creatinine categories. All analyses were performed with SAS version 9.1 (SAS, Cary, NC); All P values were two tailed, and a P value \<0.05 was considered statistically significant.

Results
=======

Of the 27 939 participating women, 14 979 (53.6%) had a GFR ≥90 ml/min/1.73 m^2^, 8073 (28.9%) had a GFR of 75-89 ml/min/1.73 m^2^, 3572 (12.8%) had a GFR of 60-74 ml/min/1.73 m^2^, and 1315 (4.7%) had a GFR \<60 ml/min/1.73 m^2^. Table 1[](#tbl1){ref-type="table"} shows the association between baseline characteristics and GFR categories. Compared with women with a GFR ≥90 ml/min/1.73 m^2^, women with a rate \<60 ml/min/1.73 m^2^ were older, had higher total cholesterol and C reactive protein values, and were more likely to be hypertensive and to use antihypertensive drugs, be past smokers, and be more physically active.

###### 

 Age adjusted baseline characteristics of 27 939 participants in the Women's Health Study by estimated glomerular filtration rate.\* Values are percentages of participants unless stated otherwise

  Characteristics                                      Glomerular filtration rate (ml/min/1.73 m^2^)                                 
  ---------------------------------------------------- ----------------------------------------------- -------------- -------------- --------------
  Mean (SE) age (years)                                57.1 (0.22)                                     56.5 (0.13)    55.2 (0.08)    53.8 (0.05)
  Mean (SE) total cholesterol concentration (mmol/l)   6.59 (0.03)                                     5.82 (0.02)    5.50 (0.01)    5.29 (0.01)
  Mean (SE) C reactive protein concentration (mg/l)    4.2 (0.16)                                      3.5 (0.1)      3.4 (0.06)     3.8 (0.05)
  Mean (SE) body mass index (kg/m^2^)                  26.0 (0.14)                                     25.9 (0.08)    25.8 (0.06)    26.0 (0.04)
  Body mass index ≥30 kg/m^2^                          18.8                                            17.1           16.6           18.3
  Mean (SE) systolic blood pressure (mm Hg)            123.9 (0.37)                                    123.2 (0.22)   123.2 (0.15)   124.1 (0.11)
  Hypertension                                         27.4                                            25.0           23.7           25.6
  Antihypertensive treatment                           16.6                                            14.0           12.4           13.4
  Diabetes                                             2.4                                             2.1            2.1            2.7
  Smoking status:                                                                                                                    
   Never                                               51.3                                            51.9           52.8           51.0
   Past                                                37.6                                            36.7           36.4           36.7
   Current                                             11.1                                            11.5           10.8           12.3
  Alcohol consumption:                                                                                                               
   Rarely/never                                        42.7                                            43.8           42.2           45.3
   \<1 drink/week                                      13.1                                            13.1           13.3           13.4
   1-6 drinks/week                                     34.4                                            33.2           33.6           31.1
   ≥1 drinks/day                                       9.7                                             9.9            10.9           10.3
  Physical activity:                                                                                                                 
   Rarely/never                                        34.9                                            36.7           35.4           38.5
   \<1 time/week                                       18.5                                            18.5           19.0           20.1
   2-3 times/week                                      33.1                                            32.6           33.7           30.7
   ≥4 times/week                                       13.6                                            12.2           12.0           10.7
  Postmenopausal hormone use:                                                                                                        
   Never                                               47.6                                            48.2           49.8           47.9
   Past                                                9.3                                             9.6            8.9            8.7
   Current                                             43.1                                            42.2           41.3           43.5
  Randomised to aspirin use                            49.4                                            49.8           50.7           49.8

\*Estimated with the Modification of Diet in Renal Disease Study equation.^23^

Proportions may not add up to 100% because of rounding and missing values.

SE = standard error.

During a mean of 12 years of follow-up (339 303 person years), 1199 participants had at least one incident cardiovascular event (non-fatal stroke, non-fatal myocardial infarction, coronary revascularisation procedure, or death from a cardiovascular cause) and 856 women died, with 179 of the deaths caused by cardiovascular disease. We found no association between GFR categories and risk of any cardiovascular event or death from any cause. Compared with women with GFR ≥90 ml/min/1.73 m^2^, the multivariable adjusted hazard ratios for any first cardiovascular disease event were 0.95 (95% confidence interval 0.83 to 1.08), 0.84 (0.70 to 1.00), and 1.00 (0.79 to 1.27) among women with GFR of 75-89.9, 60-74.9, and \<60 ml/min/1.73 m^2^ respectively; and for all-cause mortality the hazard ratios were 0.93 (0.79 to 1.09), 1.03 (0.85 to 1.26), and 1.09 (0.83 to 1.45) respectively. We further found no association between GFR and myocardial infarction, coronary revascularisation procedures, stroke, or non-cardiovascular death. Comparing women with a GFR \<60 ml/min/1.73 m^2^ with women with a rate of ≥90 ml/min/1.73 m^2^, the multivariable adjusted hazard ratios were 1.03 (0.79 to 1.33) for myocardial infarction, 0.83 (0.59 to 1.17) for coronary revascularisation procedures, 1.03 (0.70 to 1.53) for stroke, and 0.92 (0.65 to 1.29) for non-cardiovascular death (table 2[](#tbl2){ref-type="table"}). With regard to stroke subtypes, our data indicated no increased risk for the ischaemic or haemorrhagic stroke subtype: compared with women with a GFR ≥90 ml/min/1.73 m^2^, women with a rate \<60 ml/min/1.73 m^2^ had adjusted hazard ratios of 1.11 (0.73 to 1.69) for ischaemic stroke and 0.66 (0.20 to 2.19) for haemorrhagic stroke.

###### 

 Hazard ratios (95% confidence intervals) for cardiovascular events and mortality among 27 939 participants in the Women's Health Study by estimated glomerular filtration rate.\* Hazard ratios are adjusted for age and for multiple variables†

  Event                                       Glomerular filtration rate (ml/min/1.73 m^2^)   P value for trend‡                                    
  ------------------------------------------- ----------------------------------------------- --------------------- --------------------- --------- ------
  Any cardiovascular event (n=1199)§:         (n=84)                                          (n=165)               (n=347)               (n=603)   
   Age adjusted                               1.13 (0.90 to 1.42)                             0.86 (0.73 to 1.03)   0.93 (0.81 to 1.06)   1.00      0.53
   Multiple adjusted                          1.00 (0.79 to 1.27)                             0.84 (0.70 to 1.00)   0.95 (0.83 to 1.08)   1.00      0.22
  Myocardial infarction (n=313):              (n=17)                                          (n=50)                (n=94)                (n=152)   
   Age adjusted                               0.91 (0.55 to 1.50)                             1.04 (0.75 to 1.43)   1.00 (0.77 to 1.29)   1.00      0.91
   Multiple adjusted                          1.03 (0.79 to 1.33)                             0.99 (0.71 to 1.37)   0.80 (0.48 to 1.34)   1.00      0.63
  Coronary revascularisation (n=675)¶:        (n=39)                                          (n=90)                (n=197)               (n=349)   
   Age adjusted                               0.96 (0.69 to 1.33)                             0.86 (0.68 to 1.08)   0.93 (0.78 to 1.11)   1.00      0.27
   Multiple adjusted                          0.83 (0.59 to 1.17)                             0.81 (0.64 to 1.02)   0.95 (0.80 to 1.14)   1.00      0.08
  Stroke (n=389):                             (n=31)                                          (n=50)                (n=111)               (n=197)   
   Age adjusted                               1.20 (0.82 to 1.77)                             0.76 (0.55 to 1.04)   0.88 (0.70 to 1.12)   1.00      0.52
   Multiple adjusted                          1.03 (0.70 to 1.53)                             0.74 (0.54 to 1.02)   0.90 (0.71 to 1.14)   1.00      0.29
  All-cause mortality (n=856):                (n=60)                                          (n=139)               (n=236)               (n=421)   
   Age adjusted                               1.10 (0.84 to 1.45)                             1.00 (0.82 to 1.21)   0.88 (0.75 to 1.04)   1.00      0.99
   Multiple adjusted                          1.09 (0.83 to 1.45)                             1.03 (0.85 to 1.26)   0.93 (0.79 to 1.09)   1.00      0.77
  Cardiovascular disease death (n=179):       (n=21)                                          (n=32)                (n=43)                (n=83)    
   Age adjusted                               1.77 (1.09 to 2.88)                             1.07 (0.71 to 1.62)   0.78 (0.54 to 1.13)   1.00      0.18
   Multiple adjusted                          1.68 (1.02 to 2.79)                             1.18 (0.77 to 1.79)   0.87 (0.60 to 1.27)   1.00      0.13
  Non-cardiovascular disease death (n=677):   (n=39)                                          (n=107)               (n=193)               (n=338)   
   Age adjusted                               0.92 (0.66 to 1.28)                             0.98 (0.78 to 1.22)   0.91 (0.76 to 1.09)   1.00      0.48
   Multiple adjusted                          0.92 (0.65 to 1.29)                             1.00 (0.65 to 1.25)   0.94 (0.79 to 1.13)   1.00      0.62

\*Estimated with the Modification of Diet in Renal Disease Study equation.^23^

†Adjusted for age, systolic blood pressure, antihypertensive treatment, smoking, body mass index, alcohol consumption, exercise, total cholesterol, C reactive protein, use of hormone replacement therapy, diabetes, and assigned treatments.

‡P for trend across median values of the GFR categories.

§Defined as the first of any of non-fatal stroke, non-fatal myocardial infarction, coronary revascularisation procedure, or death from cardiovascular cause.

¶Includes reports of bypass surgery or percutaneous coronary angioplasty.

We found a significantly increased risk of cardiovascular death (hazard ratio 1.68 (1.02 to 2.79)) for women with a GFR \<60 ml/min/1.73 m^2^ compared with women with a GFR ≥90 ml/min/1.73 m^2^. However, this increased risk was limited to women in the low GFR group, and we found no significant linear trend across GFR categories (table 2[](#tbl2){ref-type="table"}).

When we further subcategorised the low GFR group to \<40 ml/min/1.73 m^2^, we found increased risk of death from any cause (hazard ratio 2.26 (1.15 to 4.41)) for the 67 women in that category, which was driven by increased risk of death from cardiovascular disease (3.06 (0.94 to 9.94)), when compared with the high GFR group. In contrast, there was no significant association with other cardiovascular disease end points with the highest point estimate for stroke (hazard ratio 1.31 (0.41 to 4.13)).

Table 3[](#tbl3){ref-type="table"} summarises the association between categories of creatinine concentration and risk of the various outcomes. Overall, the pattern of association was similar to that found with the GFR categories. Compared with women with a creatinine concentration below the 50th centile, women with concentrations ≥95th centile had multivariable adjusted hazard ratios of 0.99 (0.78 to 1.26) for any cardiovascular disease, 0.86 (0.51 to 1.43) for myocardial infarction, 0.82 (0.58 to 1.16) for coronary revascularisation, 0.99 (0.66 to 1.47) for stroke, 1.10 (0.83 to 1.46) for all-cause mortality, 1.74 (1.05 to 2.89) for cardiovascular mortality, and 0.92 (0.65 to 1.29) for non-cardiovascular mortality.

###### 

 Hazard ratios (95% confidence intervals) for cardiovascular events and mortality among 27 939 participants in the Women's Health Study by blood creatinine concentration. Hazard ratios are adjusted for age and for multiple variables\*

  Event                                       Creatinine concentration (centiles)†   P value for trend‡                                                
  ------------------------------------------- -------------------------------------- --------------------- --------------------- --------------------- ------
  Any cardiovascular event (n=1199)§:         (n=604)                                (n=275)               (n=239)               (n=81)                
   Age adjusted                               1.00                                   0.90 (0.78 to 1.04)   0.91 (0.78 to 1.05)   1.14 (0.90 to 1.44)   0.95
   Multiple adjusted                          1.00                                   0.92 (0.80 to 1.06)   0.89 (0.77 to 1.04)   0.99 (0.78 to 1.26)   0.41
  Myocardial infarction (n=313):              (n=146)                                (n=81)                (n=69)                (n=17)                
   Age adjusted                               1.00                                   1.10 (0.84 to 1.45)   1.08 (0.81 to 1.44)   0.99 (0.60 to 1.64)   0.76
   Multiple adjusted                          1.00                                   1.13 (0.86 to 1.49)   1.06 (0.79 to 1.42)   0.86 (0.51 to 1.43)   0.83
  Coronary revascularisation (n=675)¶:        (n=342)                                (n=161)               (n=134)               (n=38)                
   Age adjusted                               1.00                                   0.94 (0.78 to 1.13)   0.91 (0.75 to 1.12)   0.97 (0.69 to 1.35)   0.51
   Multiple adjusted                          1.00                                   0.95 (0.79 to 1.15)   0.87 (0.71 to 1.07)   0.82 (0.58 to 1.16)   0.13
  Stroke (n=389):                             (n=206)                                (n=80)                (n=74)                (n=29)                
   Age adjusted                               1.00                                   0.77 (0.59 to 0.99)   0.81 (0.62 to 1.05)   1.17 (0.79 to 1.72)   0.73
   Multiple adjusted                          1.00                                   0.78 (0.60 to 1.01)   0.80 (0.61 to 1.04)   0.99 (0.66 to 1.47)   0.34
  All-cause mortality (n=856):                (n=433)                                (n=179)               (n=186)               (n=58)                
   Age adjusted                               1.00                                   0.82 (0.69 to 0.97)   0.97 (0.82 to 1.15)   1.13 (0.86 to 1.49)   0.74
   Multiple adjusted                          1.00                                   0.85 (0.71 to 1.01)   1.01 (0.85 to 1.20)   1.10 (0.83 to 1.46)   0.67
  Cardiovascular disease death (n=179):       (n=84)                                 (n=34)                (n=41)                (n=20)                
   Age adjusted                               1.00                                   0.80 (0.54 to 1.19)   1.07 (0.74 to 1.56)   1.91 (1.17 to 3.12)   0.03
   Multiple adjusted                          1.00                                   0.87 (0.58 to 1.30)   1.18 (0.80 to 1.72)   1.74 (1.05 to 2.89)   0.04
  Non-cardiovascular disease death (n=677):   (n=349)                                (n=145)               (n=145)               (n=38)                
   Age adjusted                               1.00                                   0.82 (0.68 to 1.00)   0.95 (0.78 to 1.15)   0.93 (0.66 to 1.30)   0.45
   Multiple adjusted                          1.00                                   0.84 (0.69 to 1.03)   0.97 (0.80 to 1.18)   0.92 (0.65 to 1.29)   0.51

\*Adjusted for age, systolic blood pressure, antihypertensive treatment, smoking, body mass index, alcohol consumption, exercise, total cholesterol, C reactive protein, use of hormone replacement therapy, diabetes, and assigned treatments.

†Equivalent to ≤63 μmol/l, 64-70 μmol/l, 71-88 μmol/l, ≥89 μmol/l.

‡P for trend across median values of the creatinine categories.

§Defined as the first of any of non-fatal stroke, non-fatal myocardial infarction, coronary revascularisation procedure, or death from cardiovascular cause.

¶Includes reports of bypass surgery or percutaneous coronary angioplasty.

Lastly, we did not find evidence that the lack of association between GFR and overall cardiovascular disease was modified by age (P interaction=0.19), body mass index (P interaction=0.49), history of hypertension (P interaction=0.14), smoking status (P interaction=0.92), and total cholesterol concentration (P interaction=0.65). With regard to all-cause mortality, we found significant effect modification by history of hypertension (P interaction=0.02) suggesting increased risk of death from any cause for women with a history of hypertension (hazard ratio 1.31 (0.92 to 1.86)). The association between GFR and all-cause mortality was not modified by age, body mass index, smoking status, or total cholesterol (all P interaction ≥0.1).

Discussion
==========

In this large prospective cohort of mostly white women who were aged ≥45 and free of cardiovascular disease and other major disease including symptomatic kidney disease at study entry, we did not observe an increased risk of any cardiovascular disease event or mortality for the more than 11 000 women with GFR between 60 and 89 ml/min/1.73 m^2^, data we believe both important and reassuring given recent suggestions of a link between renal impairment and incident cardiovascular disease. Our results further indicate that a GFR \<60 ml/min/1.73 m^2^ seemed to be associated with increased risk of cardiovascular death but not with any other first cardiovascular event or non-cardiovascular mortality when compared with women with a GFR ≥90 ml/min/1.73 m^2^. When we evaluated creatinine concentration rather than estimated GFR, the associations with cardiovascular disease and mortality were similar.

Comparison with other studies
-----------------------------

Several studies have found increased risk of cardiovascular disease for individuals with impaired kidney function.[@ref10] [@ref13] [@ref14] [@ref26] [@ref27] [@ref28] However, most of these studies were of patients with existing cardiovascular disease or who were at high risk for cardiovascular disease or were limited to individuals aged 65 and above.[@ref26] [@ref27] [@ref28] Two studies were published from the population based, prospective Cardiovascular Health Study, which included individuals aged 65 and above. The first evaluated the association between creatinine concentration and cardiovascular outcomes.[@ref27] Results indicated steadily increasing risk of all-cause mortality, cardiovascular mortality, non-cardiovascular mortality, overall cardiovascular disease, and congestive heart failure with increasing levels of creatinine. The second study assessed several measures of kidney function---including creatinine levels, estimated GFR, and cystatin C concentration---all of which were associated with increased risk of all-cause mortality, cardiovascular mortality, myocardial infarction, and stroke.[@ref26] However, participants in the Cardiovascular Health Study were older and were considerably sicker than participants in the Women's Health Study and included patients with existing cardiovascular disease, congestive heart failure, and cancer, which may explain the different findings compared with our study with regard to non-fatal cardiovascular disease.

In a large, community based study using administrative data, impaired GFR was strongly associated with all-cause mortality, cardiovascular events, and rates of hospitalisation.[@ref13] However, the evaluated GFR ranges were much lower than in our study, and individuals with prior stroke, transient ischaemic attacks, peripheral artery disease, and chronic heart failure were included. Compared with participants with a GFR ≥60 ml/min/1.73 m^2^, participants with a GFR \<15 ml/min/1.73 m^2^ had adjusted hazard ratios ranging from 3.1 (95% confidence interval 3.0 to 3.3) for any hospitalisation to 5.9 (5.4 to 6.5) for death from any cause. Another study showed similar results indicating that patients with prior myocardial infarction and severe renal dysfunction (GFR \<45 ml/min/1.73 m^2^) had increased risk for recurrent coronary events.[@ref29] However, even in this high risk population, risks were not increased among those with less severe levels of kidney impairment (GFR 60-74 ml/min/1.73 m^2^). When we further subdivided our low GRF group to values of \<40 ml/min/1.73 m^2^, we observed increased risk of all-cause mortality, which was driven by cardiovascular mortality. However, we only had 67 women in this category, which limits any interpretation of these findings.

Further, in a cohort of 37 153 individuals who were screened in the National Kidney Foundation's Kidney Early Evaluation Program and who were followed for a median of 16 months, three measures of chronic kidney disease (GFR \<60 ml/min/1.73 m^2^, microalbuminuria \>30 mg/l, and anaemia) were associated with increased risk of death. Further, participants who had all three factors present had the lowest survival.[@ref30] In the Women's Health Study no information on microalbuminuria or anaemia was available.

With regard to stroke subtypes, findings from the Rotterdam Study indicated increased risk of haemorrhagic stroke for individuals with decreased kidney function.[@ref31] Compared with participants with the highest quarter of GFR values, those with the lowest values had a hazard ratio (adjusted for age and sex) of 4.10 (1.25 to 13.42). Our data do not indicate an association between kidney function and haemorrhagic stroke, but the low number of such events in our study (n=73) and in the Rotterdam Study (n=44) means the results should be interpreted cautiously. Similar to our data, there was no association with ischaemic stroke in the data from the Netherlands.

The overall epidemiological evidence associating impaired kidney function with risk of cardiovascular disease and mortality suggests that individuals with a GFR \<60 ml/min/1.73 m^2^ are at increased risk of cardiovascular death, and the risk steadily increases with decreasing GFR values below 60. The increased risk of myocardial infarction and stroke as well as non-cardiovascular mortality may be limited to individuals with existing cardiovascular disease or who are at high risk for cardiovascular disease events. In addition, patients with GFR \<30 ml/min/1.73 m^2^ may be at increased risk for all cardiovascular disease events and all-cause mortality.

The association between kidney function and cardiovascular disease is complex. It has been shown that risk factors for cardiovascular disease also predict impaired kidney function. For example, in the Framingham Heart Study, body mass index, smoking, and diabetes are predictors of impaired kidney function.[@ref7] Furthermore, data from the Physicians' Health Study indicated that higher cholesterol levels,[@ref6] high body mass index,[@ref9] and abstaining from drinking alcohol[@ref8] were risk factors for chronic kidney disease. Thus, impaired kidney function may be a marker for individuals with a more unfavourable cardiovascular disease risk profile and not a biological risk factor per se for subsequent cardiovascular disease.

Strengths and limitations of study
----------------------------------

Our study has several strengths, including the large number of participants and outcome events, high participation rate and long follow-up, confirmed cardiovascular disease events after medical record review, the homogeneity of the study (which may reduce bias), and available information on a large number of potential confounding factors.

Several limitations should be considered when interpreting our results. First, creatinine concentration was measured only once, and thus change of creatinine over time could not be evaluated.

Second, we used the Modification of Diet in Renal Disease Study equation to estimate GFR, which may result in misclassification of kidney function. However, the equation predicts GFR well, and its use is recommend by the National Kidney Foundation.[@ref24] In addition, when we used creatinine categories or the Cockcroft-Gault equation[@ref32] (data not shown) to estimate kidney function, we found a similar pattern of association between impaired kidney function and cardiovascular disease events. We had no other measures of impaired kidney function available, such as microalbuminuria or cystatin C. Cystatin C may be a better marker of chronic kidney disease than creatinine and may be a better predictor for cardiovascular disease.[@ref28]

Third, despite adjustment for a large number of potential confounders, residual and unmeasurable confounding may be present since our data are observational.

Fourth, although the overall number of outcome events was large, we had limited numbers of individual events in each of the GFR subgroups, so our findings should be interpreted cautiously.

Lastly, all participants were female health professionals and most of them white, which may limit generalisability to other populations. Indeed, data suggest that the association between impaired kidney function and cardiovascular disease or mortality is more apparent in black people[@ref14] and men.[@ref18]

Conclusions
-----------

Data from this large prospective cohort of women without prior cardiovascular disease or other major disease at study entry do not indicate an association between mild to moderate kidney impairment and increased risk of cardiovascular disease or mortality. Impaired kidney function (GFR \<60 ml/min/1.73 m^2^) seemed to be associated with an increased risk of cardiovascular disease death but not other cardiovascular or mortality outcomes, a finding that deserves further investigations.

### What is already known on this topic

1.  Impaired kidney function has been associated with increased risk of cardiovascular disease and mortality among patients with existing kidney disease or existing cardiovascular disease

### What this study adds

1.  This large prospective study of women free of vascular disease or symptomatic kidney disease at baseline indicates no association between kidney function and major cardiovascular disease or all-cause mortality

2.  Impaired kidney function (glomerular filtration rate \<60 ml/min/1.73 m^2^) seemed to be associated with an increased risk of cardiovascular disease death but was not associated with any other cardiovascular or mortality outcome
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